🇺🇸 FDA

Company profile · Sponsor

Revolution

Revolution Medicines

RVMD · NYSE biotech REDWOOD CITY, CA, USA
Pipeline
24
Drugs
0
Patents
8

Quick answer

Revolution (RVMD) is a biotech company. headquartered in REDWOOD CITY, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker RVMD
Exchange NYSE
Company type biotech
Headquarters REDWOOD CITY, CA, USA
SEC CIK 0001628171

Pipeline (24)

Search pipeline →

  1. DARAXONRASIB (RMC-6236), DARAXONRASIB (RMC-6236)

    Revolution

    Resected Pancreatic Ductal Adenocarcinoma (PDAC)

    phase 3 small molecule active

    1 trial

  2. DARAXONRASIB (RMC-6236), DOCETAXEL, DARAXONRASIB (RMC-6236)

    Revolution

    non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  3. DARAXONRASIB (RMC-6236), GEMCITABINE HYDROCHLORIDE, PACLITAXEL ALBUMIN-BOUND, GEMCITABINE HYDROCHLORIDE, OXALIPLATIN, GEMCITABINE HYDROCHLORIDE, DARAXONRASIB (RMC-6236), GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, IRINOTECAN, IRINOTECAN HYDROCHLORIDE, FOLINIC ACID, FLUOROURACIL, GEMCITABINE HYDROCHLORIDE

    Revolution

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  4. RMC-6236

    Revolution

    Pancreatic Cancer

    phase 3 small molecule active

    1 trial

  5. daraxonrasib

    Revolution

    NSCLC (Non-small Cell Lung Cancer)

    phase 3 small molecule active

    1 trial

  6. daraxonrasib

    Revolution

    Pancreatic Cancer

    phase 3 small molecule active

    2 trials

  7. Daraxonrasib

    Revolution

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  8. Elironrasib

    Revolution

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  9. PEMBROLIZUMAB, DARAXONRASIB (RMC-6236), CARBOPLATIN, DARAXONRASIB (RMC-6236), PEMETREXED, CISPLATIN, RMC-9805

    Revolution

    Lung Cancer

    phase 2 small molecule active

    1 trial

  10. RMC-4630

    Revolution

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  11. RMC-4630

    Revolution

    Solid Tumor

    phase 2 small molecule completed

    1 trial

  12. RMC-6236

    Revolution

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  13. RMC-6236

    Revolution

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  14. RMC-6291

    Revolution

    Non-Small Cell Lung Cancer, NSCLC

    phase 2 small molecule active

    2 trials

  15. RMC-9805

    Revolution

    Lung Cancer

    phase 2 small molecule active

    1 trial

  16. TNG462

    Revolution

    PDAC

    phase 2 small molecule active

    1 trial

  17. Vociprotafib

    Revolution

    Metastatic Neoplasm

    phase 2 small molecule terminated

    1 trial

  18. A study to see how combination of RMC-6291 and RMC-6236 is tolerated in multiple different dosages in participants with Advanced KRASG12C-mutated Solid Tumors

    Revolution

    Participants with Advanced KRASG12C-Mutated Solid Tumors

    phase 1 other active

    1 trial

  19. Pemetrexed STADA 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, RMC-6236, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., CARBOPLATIN-EBEWE, 10 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO

    Revolution

    Lung Cancer

    phase 1 small molecule active

    1 trial

  20. Pemetrexed Synthon 25 mg/ml, concentraat voor oplossing voor infusie, DARAXONRASIB (RMC-6236), Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DARAXONRASIB (RMC-6236), Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Pemetre

    Revolution

    Lung Cancer

    phase 1 small molecule active

    1 trial

  21. Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors.

    Revolution

    Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor, Colorectal Cancer (CRC)

    phase 1 other active

    1 trial

  22. RMC-4630

    Revolution

    Solid Tumors

    phase 1 small molecule active

    1 trial

  23. RMC-5127

    Revolution

    Non-small Cell Lung Cancer (NSCLC)

    phase 1 small molecule active

    1 trial

  24. RMC-5552

    Revolution

    Solid Tumors

    phase 1 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12409225

    Ras inhibitors

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12403196

    Ras inhibitors

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12384750

    Ras inhibitors

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12365688

    Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12280113

    Ras inhibitors

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12258366

    Bicyclic heteroaryl compounds and uses thereof

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12252497

    Ras inhibitors

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12202845

    Ras inhibitors

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Revolution?

Revolution (RVMD) is a biotech company. headquartered in REDWOOD CITY, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Revolution sponsor?

We track 24 ClinicalTrials.gov-linked programs for Revolution, including DARAXONRASIB (RMC-6236), DARAXONRASIB (RMC-6236) and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Revolution company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.